Flagship company Torque raises $21M in series A

Immunotherapy play Torque Therapeutics Inc. (Cambridge, Mass.) raised $21 million, according to an SEC filing, in the first tranche of a $35 million series A round led by undisclosed investors. Torque is a Flagship Pioneering portfolio company.

Founded in 2016, Torque is using its Deep-Priming technology platform to fuse immune response agonists -- stimulatory cytokines, antibodies, and small molecules -- to immune cells in order to optimize dose, timing and location in the tumor microenvironment. The company said it will apply the platform across all types of immune cell therapies, including chimeric antigen receptor (CAR) T, T cell receptor (TCR) and NK cells. ...